WellDoc Names Biotech Veteran as President

  WellDoc Names Biotech Veteran as President

  Kevin McRaith, former Human Genome Sciences and Genentech executive joins
                           WellDoc Management Team

Business Wire

BALTIMORE -- March 13, 2014

WellDoc®, developers of the first FDA-cleared, mobile prescription therapy,
BlueStar^TM, announced today that Kevin P. McRaith has joined the Company as
President. Mr. McRaith most recently held the position of Vice President,
Sales & Marketing at Human Genome Sciences and held similar leadership roles
at Genentech and Abbott after starting his career at Baxter Healthcare. He
will report to Ryan Sysko, CEO of WellDoc.

"Kevin brings a wealth of experience in successfully launching life sciences
products and I look forward to him joining WellDoc’s management team,” said
Mr. Sysko. “WellDoc’s primary focus, as Kevin joins us, will be the
commercialization of BlueStar following a successful and pioneering research
and development period, which WellDoc devoted to clinical, regulatory, and
business model innovation for Mobile Prescription Therapies.”

Mr. McRaith has more than 20 years of experience commercializing therapies for
oncology, immunology, HIV, oncology, CNS and cardiology most recently with
Human Genome Sciences. Prior to that McRaith was the Vice President, Sales and
Marketing for Genentech's Hematology Franchise, where he led the commercial
efforts for the top-selling biologic, Rituxan (rituximab). Before joining
Genentech in 2005, Mr. McRaith served with Abbott Laboratories for 15 years,
where he held a number of senior positions in sales and marketing, with
responsibilities that included several major product launches. Mr. McRaith
also spent several years in sales and marketing with Baxter Healthcare
Corporation. Mr. McRaith received his Bachelor of Science degree from the
University of Iowa.

“Kevin McRaith was instrumental in Human Genome Sciences’ launch of Benlysta,
the first drug approved for lupus in over 50 years. During his tenure, Kevin
was one of our key leaders as we built our commercial organization and, as the
project team lead for Benlysta, he played a significant role within our
research and development organization. I know he will have tremendous success
at WellDoc in pioneering a new therapeutic class of products known as Mobile
Prescription Therapies,” said H. Thomas Watkins, former CEO of Human Genome
Sciences, Immediate Past Chair of the Biotechnology Industry Organization
(BIO), and a WellDoc Advisory Board Member.

In conjunction with this move, current President, Dr. Anand K. Iyer, will
assume a new role of Chief Data Science Officer. With a dissertation in
pattern recognition from Carnegie Mellon University, he will accelerate
enhancements to WellDoc’s analytics engine and predictive modeling
capabilities. “The launch of BlueStar unleashes new opportunities to advance
our core competency of transforming data into actionable knowledge that drives
behavior change, optimizes clinical decisions, and enhances outcomes,”
explained Iyer.

About WellDoc: Engaging Patients, Enhancing Outcomes™

WellDoc, a healthcare behavioral science and technology company that develops
solutions aimed at engaging patients and enhancing health outcomes, is focused
on simplifying the way chronic diseases are managed through a collaborative,
life-changing approach that breaks down the barriers of engagement and
adherence by providing patients and their healthcare providers with real-time,
actionable information. WellDoc has developed an industry-leading,
technology-based platform designed to help people with chronic diseases better
manage their conditions. Forbes selected WellDoc as one of “America's Most
Promising Companies” based on its potential for future growth, and in January
2014, WellDoc closed a $20 million Series A led by the Merck Global Health
Innovation Fund. For more information visit: www.welldoc.com.


For WellDoc
Sean O’Brien, 202-223-4933
Press spacebar to pause and continue. Press esc to stop.